R
RNAimmune
Biotech & Life Sciences · Gaithersburg, United States · Founded 2020
The company's focus is on developing treatments and cures for complex diseases using mrna technology MoreLess
RNAimmune is a biotechnology startup specializing in messenger RNA (mRNA) technology. The company focuses on developing treatments for cancer, antibody therapies, rare diseases, and prophylactic vaccines. RNAimmune's proprietary technology uses mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company operates in the biotechnology and pharmaceutical markets, serving clients in the healthcare sector, including hospitals, research institutions, and pharmaceutical companies. RNAimmune generates revenue through the development and licensing of its mRNA-based therapies and vaccines. The company's leadership team includes industry veterans with extensive experience in drug development and pharmaceutical research, ensuring a strong foundation for innovation and growth.
Keywords: mRNA technology, cancer therapies, antibody treatments, rare diseases, vaccines, biotechnology, pharmaceutical, healthcare, drug development, innovation.
Company overview
RNAimmune company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Gaithersburg, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 33.1
Valuation & funding
RNAimmune funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Mar 2022 | $27M | $108M | Rotating Boulder Fund · Sirnaomics | ↗ |
| SEED✓Equity / VC | Apr 2021 | $10M | $40M | Terra Magnum Capital Partners · Smooth River · High Forest Investment · Shanghai Walga Biotechnology | — |
| SEED✓Equity / VC | Aug 2020 | $2.4M | $9.4M | Terra Magnum Capital Partners | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 8 |
| 2025 | 9 |
| 2024 | 15 |
| 2023 | 19 |
| 2022 | 15 |
| 2021 | 8 |
Growth signals
RNAimmune website traffic
Latest recorded traffic for RNAimmune is 1.8K monthly website visits, up 80% over the last three months. RNAimmune's team grew 0% over the past year.
Comparisons
RNAimmune compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
RNAimmune's talent
Source: Dealroom Talent Intelligence.
Investors
7 investors on RNAimmune's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where RNAimmune has talent and traffic
team presence
In the news
Latest news about RNAimmune
Recent press, funding announcements, and product moves mentioning RNAimmune — open to read from the original sources.
Market sentiment
What the market is saying about RNAimmune
An AI-synthesized read of the highest-engagement posts about RNAimmune on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See RNAimmune’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.